Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7305)
All Articles published online
|
Publishing Process of This Article
|
Dec 28, 2020 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Qi X, Yang M, Stenberg J, Dey R, Fogwe L, Alam MS, Kimchi ET, Staveley-O'Carroll KF, Li G. Gut microbiota mediated molecular events and therapy in liver diseases. World J Gastroenterol 2020; 26(48): 7603-7618 [PMID: 33505139 DOI: 10.3748/wjg.v26.i48.7603] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v26/i48/7603.htm |
| Number | Citing Articles |
| 1 |
Stanislav Konstantinovich Gruzdev, Irina Viktorovna Podoprigora, Oksana Anatolievna Gizinger. Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets. Archives of Microbiology 2024; 206(2) doi: 10.1007/s00203-023-03752-0
|
| 2 |
Ming Yang, Lea Khoukaz, Xiaoqiang Qi, Eric T. Kimchi, Kevin F. Staveley-O’Carroll, Guangfu Li. Diet and Gut Microbiota Interaction-Derived Metabolites and Intrahepatic Immune Response in NAFLD Development and Treatment. Biomedicines 2021; 9(12): 1893 doi: 10.3390/biomedicines9121893
|
| 3 |
Xiaoqiang Qi, Yajun Liu, Samira Hussein, Grace Choi, Eric T. Kimchi, Kevin F. Staveley-O’Carroll, Guangfu Li. The Species of Gut Bacteria Associated with Antitumor Immunity in Cancer Therapy. Cells 2022; 11(22): 3684 doi: 10.3390/cells11223684
|
| 4 |
Miguel Angel Martinez, Sandra Franco. Impact of COVID‐19 in Liver Disease Progression. Hepatology Communications 2021; 5(7): 1138 doi: 10.1002/hep4.1745
|
| 5 |
Han Yu, Zhijun Wang, Gang Zhao. Chronic Liver Disease and Promising
Therapeutic Strategy: A Concise Review. Pharmacognosy Magazine 2024; doi: 10.1177/09731296241228361
|
| 6 |
Motoh Iwasa, Akiko Eguchi, Yasuyuki Tamai, Ryuta Shigefuku, Ryo Nakagawa, Hiroshi Hasegawa, Jumpei Kondo, Masayuki Morikawa, Eiji Miyoshi, Hayato Nakagawa. Elevation of enterococcus-specific antibodies associated with bacterial translocation is predictive of survival rate in chronic liver disease. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.982128
|
| 7 |
Jun Zhang, Jing Zhou, Zheyun He, Hongshan Li. Bacteroides and NAFLD: pathophysiology and therapy. Frontiers in Microbiology 2024; 15 doi: 10.3389/fmicb.2024.1288856
|
| 8 |
Milena Peruhova, Monika Peshevska-Sekulovska, Tsvetelina Velikova. Interactions between human microbiome, liver diseases, and immunosuppression after liver transplant. World Journal of Immunology 2021; 11(2): 11-16 doi: 10.5411/wji.v11.i2.11
|
| 9 |
Yu-Lin Zhang, Zhen-Jiao Li, Hong-Zhong Gou, Xiao-Jing Song, Lei Zhang. The gut microbiota–bile acid axis: A potential therapeutic target for liver fibrosis. Frontiers in Cellular and Infection Microbiology 2022; 12 doi: 10.3389/fcimb.2022.945368
|
| 10 |
Chun-Ye Zhang, Shuai Liu, Ming Yang. Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy. World Journal of Gastroenterology 2022; 28(27): 3346-3358 doi: 10.3748/wjg.v28.i27.3346
|
| 11 |
Xia Niu, Yanan Meng, Jinjin Cui, Rui Li, Xiao Ding, Bingyu Niu, Ge Chang, Ning Xu, Guiling Li, Yucheng Wang, Lulu Wang. Hepatic Stellate Cell- and Liver Microbiome-Specific Delivery System for Dihydrotanshinone I to Ameliorate Liver Fibrosis. ACS Nano 2023; 17(23): 23608 doi: 10.1021/acsnano.3c06626
|
| 12 |
Tianhui Gao, Shuyi Wang, Zongping Zhu, Liting Lin, Yirong Luo, Meigui Lu, Wan Liao. Components from Curcuma longa (Turmeric) Against Hepatobiliary Diseases Based on Gut–Liver Axis: Pharmacotherapeutic Properties and Potential Clinical Applications. The American Journal of Chinese Medicine 2024; 52(02): 387 doi: 10.1142/S0192415X24500162
|
| 13 |
Song Ye, Bin Chen, Xinyu Liu, Zhengwei Zhang, Wenjing Zhao, Haoran Wang, Lingli Ren, Bing Zhao, Qian Zhou, Xi Chen, Yang Yang, Peng Cao, Juan Ye. Wangshi Baochi Pills alleviate alcoholic liver disease by regulating the gut microbiota composition in a mouse model. Pharmacological Research - Modern Chinese Medicine 2023; 6: 100208 doi: 10.1016/j.prmcm.2022.100208
|
| 14 |
Ting Wang, Taichi Ishikawa, Minoru Sasaki, Toshimi Chiba. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of Porphyromonas gingivalis. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.822190
|
| 15 |
Wenyu Luo, Shiqi Guo, Yang Zhou, Jingwen Zhao, Mengyao Wang, Lixuan Sang, Bing Chang, Bingyuan Wang. Hepatocellular Carcinoma: How the Gut Microbiota Contributes to Pathogenesis, Diagnosis, and Therapy. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.873160
|
| 16 |
Ming Yang, Katina Massad, Eric T. Kimchi, Kevin F. Staveley-O’Carroll, Guangfu Li. Gut microbiota and metabolite interface-mediated hepatic inflammation. Immunometabolism 2024; 6(1): e00037 doi: 10.1097/IN9.0000000000000037
|
| 17 |
Amedeo Amedei, Stefano Gitto, Claudia Campani, Fabio Marra. Probiotics. 2022; : 467 doi: 10.1016/B978-0-323-85170-1.00003-8
|
| 18 |
Sheng-Xia Lv, Zhang-Cheng Wang, Ying Zhu, Ling-Juan Jia, Meng Zhu, Ling-Hui Tao, Yi-Ke Wang, Fei-Ye Zhu, Yong-Sheng Zhang. Discussion on treatment of liver fibrosis with traditional Chinese medicine from the perspective of gut microbiota. World Chinese Journal of Digestology 2023; 31(21): 889 doi: 10.11569/wcjd.v31.i21.889
|
| 19 |
Münevver Demir, Frank Tacke. Darm-Leber-Achse – wie der Darm die Leber krank macht. Die Innere Medizin 2022; 63(10): 1028 doi: 10.1007/s00108-022-01398-6
|
| 20 |
Liping Li, Yongbo Kang. The Gut Microbiome and Autoimmune Hepatitis: Implications for Early Diagnostic Biomarkers and Novel Therapies. Molecular Nutrition & Food Research 2023; 67(24) doi: 10.1002/mnfr.202300043
|